SLC31A2: A promising drug target and biomarker for copper transporter 2

Target Name: SLC31A2

NCBI ID: G1318

SLC31A2: A promising drug target and biomarker for copper transporter 2

Cochlear implantation is a surgical procedure that is used to restore hearing in people with severe hearing loss or deafness. The hearing loss can be caused by various conditions, including hearing loss due to damage to the inner ear, middle ear, or inner ear nerve. One of the underlying causes of hearing loss is the dysfunction of the copper transporter 2 (Copper 2), which is a protein that is responsible for transporting copper ions from the cell surface to the inside of the cell.

SLC31A2, a protein that belongs to the SLC31 family of transport proteins, has been identified as a potential drug target and biomarker for copper 2 dysfunction. The SLC31A2 protein is expressed in the inner ear, brain, and other tissues and has been shown to play a role in the development and progression of various hearing loss conditions, including sudden hearing loss and hearing loss due to age-related hearing loss.

Dise帽algo del sitio:

Understanding the Role of Copper 2 in Hearing Loss

Cochlear implants are often used to treat hearing loss in people, but they are not always effective and can cause various side effects. One of the most common side effects of cochlear implantation is the development of hearing loss due to damage to the copper 2 transporter. This is because the copper 2 transporter is responsible for carrying copper ions from the cell surface to the inside of the cell, and any damage to this transporter can cause copper ions to accumulate outside of the cell, leading to hearing loss.

SLC31A2: A Potential Drug Target

SLC31A2 is a protein that has been shown to play a role in the development and progression of hearing loss conditions. Researchers have shown that SLC31A2 is expressed in the inner ear and that it is involved in the development of hearing loss in various animal models of hearing loss, including mice and frogs.

In addition, SLC31A2 has been shown to interact with other proteins that are involved in hearing loss, including the transcription factor CIBAH and the protein TRPV4. These interactions may suggest that SLC31A2 is involved in the regulation of hearing loss by these other proteins.

SLC31A2 as a Biomarker

SLC31A2 has also been shown to be a potential biomarker for copper 2 dysfunction. Researchers have shown that SLC31A2 is expressed in the inner ear and that it is involved in the development of hearing loss in mice and frogs. Additionally, studies have shown that SLC31A2 is involved in the regulation of hearing loss by the transcription factor CIBAH, which is known to play a role in the development of hearing loss in various models of hearing loss.

In summary, SLC31A2 is a protein that has been shown to play a role in the development and progression of hearing loss conditions. Its involvement in the regulation of hearing loss by the transcription factor CIBAH makes it a potential biomarker for copper 2 dysfunction and a potential drug target for treating hearing loss.

Conclusion

SLC31A2 is a protein that has been identified as a potential drug target and biomarker for copper 2 dysfunction. Its involvement in the regulation of hearing loss by the transcription factor CIBAH makes it a promising target for treating hearing loss. Further research is needed to understand the full role of SLC31A2 in the development and progression of hearing loss conditions and to develop safe and effective treatments.

Protein Name: Solute Carrier Family 31 Member 2

Functions: Does not function as a copper(1+) importer in vivo (By similarity). However, in vitro functions as low-affinity copper(1+) importer (PubMed:17944601, PubMed:17617060). Regulator of SLC31A1 which facilitates the cleavage of the SLC31A1 ecto-domain or which stabilizes the truncated form of SLC31A1 (Truncated CTR1 form), thereby drives the SLC31A1 truncated form-dependent endosomal copper export and modulates the copper and cisplatin accumulation via SLC31A1 (By similarity)

More Common Targets